Abvc Biopharma Inc
(ABVC)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,975 | -2,928 | -8,281 | -7,581 | -4,213 |
| Depreciation Amortization | 217 | 103 | 380 | 21 | 14 |
| Income taxes - deferred | N/A | N/A | 116 | -36 | 82 |
| Accounts receivable | N/A | N/A | 229 | 191 | 182 |
| Other Working Capital | -164 | -339 | 491 | 968 | 966 |
| Other Operating Activity | 2,755 | 2,208 | 2,879 | 2,680 | 572 |
| Operating Cash Flow | $-1,167 | $-956 | $-4,187 | $-3,756 | $-2,398 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -21 | -21 | N/A |
| Purchase Of Investment | N/A | N/A | -339 | -493 | -441 |
| Other Investing Activity | -502 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $-502 | $N/A | $-360 | $-514 | $-441 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 30 | 30 | N/A | N/A | -1,000 |
| Debt Issued | 282 | 282 | 1,463 | 1,353 | 3,175 |
| Debt Repayment | 738 | N/A | N/A | 0 | N/A |
| Common Stock Issued | 525 | 394 | 3,456 | 3,479 | N/A |
| Other Financing Activity | 152 | 218 | -1,049 | -1,000 | 0 |
| Financing Cash Flow | $1,726 | $924 | $3,870 | $3,832 | $2,175 |
| Exchange Rate Effect | -32 | -26 | 2 | 168 | 14 |
| Beginning Cash Position | 717 | 717 | 1,392 | 1,392 | 1,392 |
| End Cash Position | 743 | 659 | 717 | 1,121 | 742 |
| Net Cash Flow | $26 | $-58 | $-675 | $-271 | $-650 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,167 | -956 | -4,187 | -3,756 | -2,398 |
| Capital Expenditure | N/A | N/A | -21 | -21 | N/A |
| Free Cash Flow | -1,167 | -956 | -4,208 | -3,778 | -2,398 |